Ladero J M, Jimenez F J, Benitez J, Fernandez-Gundin M J, Martinez C, Llerena A, Cobaleda J, Muñoz J J
Department of Medicine, University Complutense of Madrid, Spain.
Eur J Clin Pharmacol. 1989;37(4):391-3. doi: 10.1007/BF00558506.
Acetylator phenotype has been determined using sulphamethazine in 100 patients with Parkinson's disease and in 93 age-matched normal control subjects. Sixty-nine patients and 54 control subjects were classified as slow acetylators (NS). No relation was found among acetylator polymorphism and age at onset or clinical stage of disease. Amongst slow acetylators, the percentage of acetylated sulphamethazine in plasma was significantly lower in patients than in controls. Despite this finding, the results do not support any relationship between acetylator polymorphism and the risk of developing Parkinson's disease.
在100例帕金森病患者和93例年龄匹配的正常对照者中，使用磺胺二甲嘧啶测定了乙酰化表型。69例患者和54例对照者被归类为慢乙酰化者（NS）。未发现乙酰化多态性与疾病发病年龄或临床分期之间存在关联。在慢乙酰化者中，患者血浆中乙酰化磺胺二甲嘧啶的百分比显著低于对照者。尽管有这一发现，但结果并不支持乙酰化多态性与患帕金森病风险之间存在任何关联。
